# Mechanism of Ocrelizumab in B-Cell Depletion ## How does ocrelizumab target CD20-positive B cells to drive B-cell depletion? Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets. ## Abstract Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors. B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability. ## Methods We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. Papers screened using: Mechanistic Focus on CD20/B-cells, Specific Depletion Mechanisms, Study Type and Mechanistic Data, Mechanistic Content Present, CD20/B-cell Relevance, Study Rigor and Detail. Records from Elicit search n = 200 Papers screened out n = 190 Papers included for extraction n = 10 ## Paper search We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex. We ran this query: “How does ocrelizumab target CD20-positive B cells to drive B-cell depletion?” The search returned 200 total results from Elicit. ## Screening We screened in sources based on their abstracts that met these criteria: - **Mechanistic Focus on CD20/B-cells**: Does this study investigate ocrelizumab’s mechanism of action on CD20-positive B cells or B-cell depletion mechanisms induced by ocrelizumab? - **Specific Depletion Mechanisms**: Does this study examine specific mechanisms of B-cell depletion including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), apoptosis, CD20 binding affinity, epitope recognition, or receptor occupancy by ocrelizumab? - **Study Type and Mechanistic Data**: Is this an in vitro, in vivo (animal model), human study, systematic review, or meta-analysis that provides mechanistic data about ocrelizumab? - **Mechanistic Content Present**: Does this study provide mechanistic data beyond solely clinical efficacy or safety outcomes? - **CD20/B-cell Relevance**: If this study investigates ocrelizumab effects on non-B cell populations, does it include reference to CD20 or B-cell depletion mechanisms? - **Study Rigor and Detail**: Is this study something other than a case report, case series, conference abstract, or preliminary report lacking sufficient mechanistic investigation or methodological detail? We considered all screening questions together and made a holistic judgement about whether to screen in each paper. ## Data extraction We asked a large language model to extract detailed information from each paper. ### CD20 Targeting - CD20 epitope specificity and binding characteristics: Targets an almost identical epitope to rituximab. - Antibody structure features: Humanized monoclonal antibody with enhanced binding to low-affinity variants of Fcγ receptor IIIa. ### Cytotoxic Mechanisms - Antibody-dependent cellular cytotoxicity (ADCC) activity: Higher ADCC activity compared to RTX, with two- to fivefold greater ADCC activity. ### Depletion Patterns - Specific B-cell subpopulations targeted: Naive and memory B cells. - B-cell populations resistant to depletion: Plasma cells. ### Depletion Kinetics - Time to initial B-cell depletion (onset): Almost complete depletion by week 2 after the first OCR dose. - Recovery timeline for different B-cell populations: B-cell levels increase to baseline or LLN in 90% of patients within 2.5 years after the last infusion. ### Molecular Determinants - Antibody type: Humanized. - Engineering for B-cell depletion: Enhanced ADCC activity. ### Comparative Mechanisms - Comparative analysis showing higher levels of ADCC compared to CDC for Ocrelizumab. ## Results ### Characteristics of Included Studies Study and key features: - J. Uchida et al., 2004: Mouse model of anti-CD20 therapy. - B. Cree et al., 2025: Review of anti-CD20 antibody evolution comparing ocrelizumab, ofatumumab, ublituximab, and rituximab. ## Mechanisms of CD20 Targeting and B-cell Depletion ### CD20 Binding Characteristics Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody was engineered through amino acid modifications in its Fc region to increase antibody-dependent cellular cytotoxicity (ADCC) activity. ### Cytotoxic Mechanisms Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. Studies in mouse models demonstrate that B-cell depletion is completely dependent on effector cell Fc receptor expression, with monocytes serving as the dominant effector cells. ### Patterns of B-cell Depletion - Ocrelizumab co-depletes CD20-positive T-cell subsets and retains CD20-negative B-cell precursors and plasma cells. ### Kinetics of Depletion and Recovery B-cell recovery shows complex kinetics varying by anatomical compartment and B-cell phenotype. ### Comparative Analysis - Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies, focusing more on ADCC. ### Secondary Effects on Immune Regulation Ocrelizumab treatment induces profound changes in the BAFF-APRIL system, enhancing regulatory IgA+ plasma cell development. ## Conclusion Anti-CD20 therapies, including ocrelizumab, provide significant clinical efficacy in multiple sclerosis, with distinct mechanisms affecting their therapeutic application. ## References - [J. Uchida et al., 2004](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-1219552/index.html) - [B. Cree et al., 2025](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-277547534/index.html) - [Thalia Pacheco-Fernández et al., 2018](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-81368773/index.html) - [Samantha Ho et al., 2023](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-256303612/index.html) - [A. Bar-Or et al., 2021](/content/review/5a67b35a-0fa7-4f6d-9881-ec59ed3dbac8/source/ss-236958170/index.html)